Combining 3D graphene-like screen-printed carbon electrode with methylene blue-loaded liposomal nanoprobes for phospholipase A2 detection.
Combining 3D graphene-like screen-printed carbon electrode with methylene blue-loaded liposomal nanoprobes for phospholipase A2 detection.
复制标题
DOI：
10.1016/j.bios.2018.11.004
复制
发表时间：
2019-02
影响因子：
12.6
通讯作者：
Yonghua Zhang;Junjie Ai;Yanan Dong;Shiyu Zhang;Q. Gao;H. Qi;Chengxiao Zhang;Zhiliang Cheng
中科院分区：
文献类型：
--
作者：
Yonghua Zhang;Junjie Ai;Yanan Dong;Shiyu Zhang;Q. Gao;H. Qi;Chengxiao Zhang;Zhiliang Cheng
磷脂酶A2（PLA 2）可作为一种独特的生物标志物，用于某些疾病的预测和诊断。因此，监测生物和临床样品中的PLA 2活性是重要的。在这项工作中，一个简单的电化学分析PLA 2活性的基础上，丝网印刷碳电极（SPCE）与3D石墨烯样表面。当含PLA 2的样品与纳米探针（即封装在纳米尺寸的磷脂脂质体中的电活性标记物亚甲蓝（MB））混合时，MB被释放并在微池中吸附/富集到SPCE表面上。采用紫外-可见分光光度法和荧光法对MB的包封和酶促释放进行了评价。通过方波伏安法（SWV）测量由于吸附的MB在SPCE上的氧化的峰电流。在5 ~ 200 U/L范围内，电流与PLA 2活性呈良好的线性关系，检出限为3 U/L。同样的方法也可用于筛选PLA 2抑制剂。因此，在这项工作中开发的富集策略可能是一个有前途的信号放大方法的灵敏度和选择性检测生物或临床样品中的PLA 2。
Phospholipase A2(PLA2) enzyme could be acted as a unique biomarker for forecasting and diagnosing certain diseases. Therefore, it is important to monitor PLA2activity in biological and clinical samples. In this work, a simple electrochemical assay for PLA2activity was developed based on a screen-printed carbon electrode (SPCE) with 3D graphene-like surface. When the PLA2-containing sample was mixed with the nanoprobes, i.e. the electroactive marker methylene blue (MB) encapsulated within nanometer-sized phospholipid liposomes, MB was released and adsorbed/enrichedin siteonto the surface of SPCE in a micro-cell. The encapsulation and enzymatic release of MB were evaluated using UV–Vis and fluorescence. The peak current due to oxidation of the adsorbed MB on the SPCE was measured by square-wave voltammetry (SWV). The current was directly linear to the PLA2activity from 5 U/L to 200 U/L with a detection limit of 3 U/L. The same method can also be used for screening PLA2inhibitors. Thus, the enrichment strategy developed in this work could be a promising signal amplification method for the sensitive and selective detection of PLA2in biological or clinical samples.